Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Biobank For MS And Other Demyelinating Diseases
NCT00445367 · View on ClinicalTrials.gov ↗
Study Summary
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.
Conditions Studied
Study Locations (10)
Massachusetts
- Beth Israel Deaconess — Boston
- University of Massachusetts Medical School — Worcester
Arizona
- Barrow Neurological Institute — Phoenix
California
- Stanford University — Stanford
Colorado
- The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver — Aurora
Georgia
- Shepherd Center — Atlanta
Maryland
- Johns Hopkins — Baltimore
New York
- Multiple Sclerosis Research Center of New York — New York
Ohio
- The Ohio State University — Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,226 participants |
| Start Date | 2006-05 |
| Est. Completion | 2036-10 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445367
The ClinicalTrials.gov registry entry for NCT00445367 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Cure Project for Multiple Sclerosis, which has 31 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00445367 reports 10 study locations spanning 9 distinct geographic areas — top geographies include Massachusetts, Arizona, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00445367 about?
NCT00445367 is a clinical study titled "Biobank For MS And Other Demyelinating Diseases". To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelat...
What is the current status of trial NCT00445367?
This trial is currently active not recruiting. The enrollment target is 3,226 participants. The study started on 2006-05. Estimated completion is 2036-10.
What conditions does trial NCT00445367 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Neuromyelitis Optica, Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT00445367?
This trial is sponsored by Accelerated Cure Project for Multiple Sclerosis, which has 31 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00445367 being conducted?
This trial has 10 study locations across Arizona, California, Colorado, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.